circus design
WASHINGTON (AP) — The United States is expected to announce that it will send $1.25 billion in military assistance to Ukraine, U.S. officials said Friday, as the Biden administration pushes to get as much aid to Kyiv as possible before leaving office on Jan. 20. The large package of aid includes a significant amount of munitions, including for the National Advanced Surface-to-Air Missile Systems and the HAWK air defense system. It also will provide Stinger missiles and 155 mm- and 105 mm artillery rounds, officials said. The officials, who said they expect the announcement to be made on Monday, spoke on condition of anonymity to provide details not yet made public. The new aid comes as Russia has launched a barrage of attacks against Ukraine’s power facilities in recent days, although Ukraine has said it intercepted a significant number of the missiles and drones. Russian and Ukrainian forces are also still in a bitter battle around the Russian border region of Kursk, where Moscow has sent thousands of North Korean troops to help reclaim territory taken by Ukraine. Earlier this month, senior defense officials acknowledged that that the Defense Department may not be able to send all of the remaining $5.6 billion in Pentagon weapons and equipment stocks passed by Congress for Ukraine before President-elect Donald Trump is sworn in. Trump has talked about getting some type of negotiated settlement between Ukraine and Russia, and spoken about his relationship with Russian President Vladimir Putin . Many U.S. and European leaders are concerned that it might result in a poor deal for Ukraine and they worry that he won't provide Ukraine with all the weapons funding approved by Congress. The aid in the new package is in presidential drawdown authority, which allows the Pentagon to take weapons off the shelves and send them quickly to Ukraine. This latest assistance would reduce the remaining amount to about $4.35 billion. Officials have said they hope that an influx of aid will help strengthen Ukraine’s hand, should Zelenskyy decide it’s time to negotiate. One senior defense official said that while the U.S. will continue to provide weapons to Ukraine until Jan. 20, there may well be funds remaining that will be available for the incoming Trump administration to spend. According to the Pentagon, there is also about $1.2 billion remaining in longer-term funding through the Ukraine Security Assistance Initiative, which is used to pay for weapons contracts that would not be delivered for a year or more. Officials have said the administration anticipates releasing all of that money before the end of the calendar year. If the new package is included, the U.S. has provided more than $64 billion in security assistance to Ukraine since Russia invaded in February 2022.SAN DIEGO, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors of the class action filed on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. HUMA securities between May 10, 2024 and October 17, 2024. Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Humacyte, Inc (HUMA) Misled Investors Regarding its Manufacturing Practices According to the complaint, Humacyte is currently engaged in engineering and manufacturing Acellular Tissue Engineered Vessel ("ATEV"), also known as "Human Acellular Vessel," which is a lab-grown blood vessel implant that can act as a replacement for an injured or damaged blood vessel. On August 9, 2024, Humacyte issued a press release announcing that the FDA "will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication." The press release disclosed in part, that, "[d]uring the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing[.]" On this news, the Company's stock price declined $1.29, or 16.4%, to close at $6.62 per share on August 12, 2024. The complaint further alleges that on October 17, 2024, the FDA released a Form 483 concerning Humacyte's Durham, North Carolina facility, which revealed violations, including "no microbial quality assurance," "no microbial testing," and inadequate "quality oversight." On this news, the Company's stock price declined $0.95, or 16.35%, to close at $4.86 per share on October 17, 2024. Plaintiff alleges that during the class period, defendants failed to disclose to investors: (1) that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma. What Now : You may be eligible to participate in the class action against Humacyte, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by January 17, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP : Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Humacyte, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/ A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5aec8844-e33a-43a5-9df0-319cc31cc1d4 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Zhang Baizhi and Yang Zi, two iconic Chinese actresses from different generations, recently appeared in a stunning photo together that captured the essence of their unique beauty and charm. The photo quickly went viral on social media, sparking discussions on the contrasting yet equally mesmerizing appeal of the two talented stars.In conclusion, Dean Henderson's belief in Manchester United's ability to challenge and compete with top teams like Manchester City highlights a mindset of determination and optimism that is vital for success in professional football. The draw against Manchester City may have been seen as a missed opportunity by some, but for Henderson and his teammates, it was a source of confidence and motivation to push forward and strive for even greater achievements in the matches to come. With a strong team spirit and a belief in their capabilities, Manchester United under Henderson's leadership is poised to make a mark in the league and pursue their goals with determination and resilience.
The move to selectively reduce the pregnancy has stirred debates concerning medical responsibility, ethics, and the financial implications of such a decision. On one hand, supporters argue that the decision to reduce the pregnancy was made in light of the potential risks to both the mother and the unborn children. Carrying multiple fetuses can result in various health complications, jeopardizing the well-being of both the mother and the babies. In such cases, selective reduction is often considered a medical necessity to ensure the survival and health of the remaining fetuses.
China Now Reaches Deepest Point on Earth
Oak Ridge sweeps Vicksburg at Florida basketball tournament
Looking ahead, Martinez expressed optimism about Muniz's prospects for the rest of the season. He highlighted the team's continued improvement and growth, emphasizing their commitment to playing attacking and entertaining football. Martinez reassured fans that Muniz would continue to push for victories and strive for success in every match they played.
- Previous: circus costume female
- Next: circus makeup